UroGen Pharma Ltd. (URGN) Q4 2025 Earnings Call Transcript
Source: SeekingAlpha
2026-03-02 12:57:58 ET
UroGen Pharma Ltd. (URGN) Q4 2025 Earnings Call March 2, 2026 10:00 AM EST
Company Participants
Vincent Perrone - Senior Director of Investor Relations
Elizabeth Barrett - President, CEO & Director
Mark Schoenberg - Chief Medical Officer
David Lin - Chief Commercial Officer
Christopher Degnan - Chief Financial Officer
...
Read the full article on Seeking Alpha
For further details see:
UroGen Pharma Ltd. (URGN) Q4 2025 Earnings Call Transcript
UroGen Pharma Ltd.
NASDAQ: URGN
URGN Trading
2.17% G/L:
$19.78 Last:
146,384 Volume:
$20.18 Open:
URGN Latest News
URGN Stock Data
$1,013,880,601
41,940,767
0.31%
40
N/A
Biotechnology & Life Sciences
Healthcare
US
Princeton
